v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash Flows From Operating Activities:    
Net loss $ (41,067,610) $ (19,764,713)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 11,043,551 6,022,287
Amortization of in-process research and development 4,014,062
Amortization of deferred financing costs 179,492
Deferred income tax expense (74,317) 792,720
Changes in operating assets and liabilities:    
Accounts receivable, net of allowances (686,235)
Inventory (339,252) (8,940,201)
Prepaid expenses (1,500,000) 1,600,000
Accounts payable (5,919,168) 4,955,797
Accrued expenses 19,980,496 8,458,554
Due to related party 471,787 6,875,556
Net Cash (Used In) Provided By Operating Activities (13,897,194)
Cash Flows From Investing Activities    
License payments (7,000,000)
Net Cash Used In Investing Activities (7,000,000)
Cash Flows From Financing Activities    
Net proceeds from notes payable 9,635,000
Net proceeds from exercise of warrants and pre-funded warrants 9,730,818
Deferred Financing Costs (892,551)  
Net proceeds from issuance of common stock 15,062,724
Net Cash Provided by Financing Activities 33,535,991
Net Change in Cash and Cash Equivalents 12,638,797
Cash and Cash Equivalents – Beginning of Period 3,924,908 112
Cash and Cash Equivalents – End of Period 16,563,705 112
Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:    
Interest Paid 212,794
Warrants issued for loan agreement included in deferred financing costs 749,280
Deferred financing costs included in accrued expenses $ 1,762,500